06/05/2002 By Robert Short
The cholesterol absorption inhibitor ezetimibe, combined with atorvastatin or simvastatin, produces further reductions in LDL cholesterol than does statin alone.
Dr Claude Gagné from the Chul du Chuq, Ste-Foy, Québec, Canada, and colleagues studied 50 patients in a muticentre, double-blind, randomized trial of people with homozygous familial hypercholesterolaemia.
The patients were on the National Cholesterol Education Program Step 1 or a stricter diet and were taking either open-label statin treatment, with or without concomitant LDL apheresis.
They received one of the following therapies for 12 weeks: one of the two statins (80 mg/d); ezetimibe (10mg/day) plus a low-dose statin (40mg/day); ezetimibe (10mg/day) plus a high dose of a statin (80mg/day).
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!